Antimalarial drugs are used for the treatment and prevention of malaria infection. This market has been growing in recent years due to the high prevalence of malaria, especially in developing and underdeveloped countries. According to the “World Malaria Report 2018” by World Health Organization (WHO), there were an estimated 219 million cases and nearly 435,000 malaria-related deaths in 2017. Hence, the high prevalence of malaria is driving the growth of this market. Other factors like an increase in awareness initiatives by Governments and research for new anti-malarial drugs and therapies are also helping this market grow.
However, side-effects of anti-malarial drugs and the presence of counterfeit and substandard drugs are restraining the growth of this market.
Scope of the Report
Antimalarial drugs are designed to treat malaria in individuals or prevent the infection in individuals who have no immunity for the infection
In the report, a detailed analysis of the Antimalarial drugs Market is provided. The market is evaluated by collating revenues generated across segments, categorized by drug class, malaria type, mechanism of action and geography.
Key Market Trends
Artemisinin compounds segment is expected to register high growth in the forecast period
According to the World malaria report, 2017 by the World Health Organization, an estimated 409 million treatment courses of artemisinin-based combination therapy (ACT) were procured by countries in 2016 which was an increase from 311 million in 2015. Over 69% of these procurements were reported to have been made for the public sector. The number of ACT treatments distributed by national malaria control programs (NMCP) in Africa to the public sector increased from 192 million in 2013 to 198 million in 2016. Most of the NMCP distributions of ACTs in 2016 occurred in the WHO African Region.
Owing to these factors, this market segment is expected to grow in the forecast period
The Middle East and Africa is one of the largest markets
According to the World Health Organization (WHO), there were an estimated 219 million cases of malaria worldwide in 2017, out of which WHO African Region carried a disproportionately high share of the global malaria burden. In 2017, the region contributed 92% of malaria cases and 93% of malaria deaths. The WHO Eastern Mediterranean Region was home for nearly 2% of the global malaria cases. Moreover, out of the total USD 2.7 billion investment in 2016 for the treatment and prevention of malaria, nearly 74% was spent in the WHO African Region.
Owing to these factors, the Middle East and Africa region is expected to have one of the largest shares in the total anti-malarial drugs market.
The majority of the anti-malarial drug are being manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market. These global players are mostly based in developed countries like United States, United Kingdom, France, Germany, and Japan. Asia-pacific is also witnessing the emergence of some small players which has helped the market growth and increased competitiveness.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- Report customization as per the client’s requirements
- 3 months of analyst support